Besides the promising results of PD-1/PD-L1 blockade immunotherapy in NPC, antibodies targeting EGFR have been reported to enhance the current treatment paradigms for locoregionally advanced NPC64. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.